{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:41:09Z","timestamp":1793810469770,"version":"4.6.1"},"reference-count":54,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"College Students\u2019 Innovation Training Program of Zhejiang Province","award":["S202513023009"],"award-info":[{"award-number":["S202513023009"]}]},{"name":"College Students\u2019 Innovation Training Program of Zhejiang Province","award":["2024R424A009"],"award-info":[{"award-number":["2024R424A009"]}]},{"name":"College Students\u2019 Innovation Training Program of Zhejiang Province","award":["2024KY057"],"award-info":[{"award-number":["2024KY057"]}]},{"name":"Scientific and Technological Innovation (Xinmiao Talents) Program of Zhejiang Province","award":["S202513023009"],"award-info":[{"award-number":["S202513023009"]}]},{"name":"Scientific and Technological Innovation (Xinmiao Talents) Program of Zhejiang Province","award":["2024R424A009"],"award-info":[{"award-number":["2024R424A009"]}]},{"name":"Scientific and Technological Innovation (Xinmiao Talents) Program of Zhejiang Province","award":["2024KY057"],"award-info":[{"award-number":["2024KY057"]}]},{"name":"Health Commission of Zhejiang Province","award":["S202513023009"],"award-info":[{"award-number":["S202513023009"]}]},{"name":"Health Commission of Zhejiang Province","award":["2024R424A009"],"award-info":[{"award-number":["2024R424A009"]}]},{"name":"Health Commission of Zhejiang Province","award":["2024KY057"],"award-info":[{"award-number":["2024KY057"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Proteolysis-targeting chimera (PROTAC) technology has demonstrated remarkable progress in tumor therapy, attributed to its unique capability of catalytically degrading \u201cundruggable\u201d targets. In the context of the ongoing global health threat posed by the Coronavirus Disease 2019 (COVID-19) pandemic, the application scope of PROTAC technology has been gradually extended to the field of antiviral research. Unlike traditional small molecule inhibitors, PROTAC employs an \u201cevent-driven\u201d mechanism to achieve ubiquitination-mediated degradation of target proteins. This approach holds great promise in addressing challenges such as drug resistance, targeting host-dependent factors, and high-mutagenic viral proteins. This article provides a comprehensive review of the application progress of PROTAC technology in antiviral therapy, with a particular emphasis on successful cases across a range of viral pathogens, including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), influenza virus, and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Additionally, it delves into the challenges encountered in this field and ponders future development directions. Through the integration of the latest research findings, this article proposes a dual-target degradation strategy based on the host\u2013pathogen interaction interface. These proposals aim to offer theoretical support for the clinical translation of antiviral PROTACs.<\/jats:p>","DOI":"10.3390\/molecules30163402","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:28:22Z","timestamp":1755523702000},"page":"3402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PROTACs in Antivirals: Current Advancements and Future Perspectives"],"prefix":"10.3390","volume":"30","author":[{"given":"Jiacheng","family":"Jin","sequence":"first","affiliation":[{"name":"Affiliated Yongkang First People\u2019s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiang","family":"Quan","sequence":"additional","affiliation":[{"name":"Affiliated Yongkang First People\u2019s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Cao","sequence":"additional","affiliation":[{"name":"Affiliated Yongkang First People\u2019s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Yongkang First People\u2019s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Yongkang First People\u2019s Hospital, Yongkang 321306, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4418-3665","authenticated-orcid":false,"given":"Zunyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Affiliated Yongkang First People\u2019s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China"},{"name":"Yongkang First People\u2019s Hospital, Yongkang 321306, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"ref_1","first-page":"113","article-title":"Emerging coronavirus diseases and future Perspectives","volume":"31","author":"Akhter","year":"2020","journal-title":"Virus Dis."},{"key":"ref_2","unstructured":"(2025, June 26). WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=c."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Hoelzemer","year":"2022","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zeng, S., Zhang, H., Shen, Z., and Huang, W. (2021). Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.639176"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bond, M.J., and Crews, C.M. (2021). Proteolysis targeting chimeras (PROTACs) come of age: Entering the third decade of targeted protein degradation. RSC Chem. Biol., 2.","DOI":"10.1039\/D1CB00011J"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Asher Mullard (2021). Targeted protein degraders crowd into the clinic. Nature Rev. Drug Discov., 20, 247.","DOI":"10.1038\/d41573-021-00052-4"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhou, C., Yang, S., Wang, J., Pan, W., Yao, H., Li, G., and Niu, M. (2025). Recent advances in PROTAC-based antiviral and antibacterial Therapeutics. Bioorg. Chem., 160.","DOI":"10.1016\/j.bioorg.2025.108437"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: Opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"Du","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4155\/fmc-2022-0005","article-title":"Proteolysis targeting chimeras in antiviral research","volume":"14","author":"Desantis","year":"2022","journal-title":"Future Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, Y., Hwang, N., Snedeker, A., Lemon, S.M., Noe, D., Sun, L., Clement, J.A., Zhou, T., Tang, L., and Block, T. (2024). \u201cPROTAC\u201d modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro. Bioorg. Med. Chem. Lett., 102.","DOI":"10.1016\/j.bmcl.2024.129680"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hahn, F., Hamilton, S.T., Wangen, C., Wild, M., Kicuntod, J., Br\u00fcckner, N., Follett, J.E.L., Herrmann, L., Kheimar, A., and Kaufer, B.B. (2021). Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312858"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","article-title":"Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","article-title":"An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.chom.2023.05.030","article-title":"Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics","volume":"31","author":"Zhao","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Blanco-Lobo, P., Nogales, A., Rodr\u00edguez, L., and Mart\u00ednez-Sobrido, L. (2019). Novel approaches for the development of live attenuated influenza vaccines. Viruses, 11.","DOI":"10.3390\/v11020190"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","article-title":"Generation of a live attenuated influenza A vaccine by proteolysis targeting","volume":"40","author":"Si","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41587-022-01406-y","article-title":"A new route to vaccines using PROTACs","volume":"40","author":"Gilbertson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chatterjee, P., Ponnapati, M., Kramme, C., Plesa, A.M., Church, G.M., and Jacobson, J.M. (2020). Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-01470-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.mayocp.2020.06.018","article-title":"Targeting TMPRSS2 in SARS-CoV-2 Infection","volume":"95","author":"Baughn","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"key":"ref_28","unstructured":"Zhang, S., Gao, M., and Wang, Z. (2023). Degradation Agent Targeting Host Cell Transmembrane Serine Protease 2 and Its Synthesis and Application. (CN115677825A)."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Al-Horani, R.A., and Kar, S. (2020). Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: A comprehensive. Viruses, 12.","DOI":"10.3390\/v12101092"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113814","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116202","DOI":"10.1016\/j.ejmech.2024.116202","article-title":"Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity","volume":"268","author":"Desantis","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/cbdd.13914","article-title":"Fragment-based in silico design of SARS-CoV-2 main protease inhibitors","volume":"98","author":"Ahmad","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112711","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1080\/07391102.2021.1953601","article-title":"Protein degradation: A novel computational approach to design protein degrader probes for main protease of SARS-CoV-2","volume":"40","author":"Shaheer","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An Overview of Severe Acute Respiratory Syndrome\u2013Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00872-e20","DOI":"10.1128\/AAC.00872-20","article-title":"Discovery of M Protease Inhibitors Encoded by SARS-CoV-2","volume":"64","author":"Hung","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","unstructured":"Li, X.B., Cheng, S.H., Bi, Y.H., Feng, Y., Wu, B.J., Shi, W.W., and Li, C.N. (2021). PROTAC Molecules Targeting SARS-CoV-2 3C Protease and Its Applications. (CN 114874204A)."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"116629","DOI":"10.1016\/j.ejmech.2024.116629","article-title":"Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses","volume":"275","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","article-title":"Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2","volume":"15","author":"Grifagni","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103847","DOI":"10.1016\/j.drudis.2023.103847","article-title":"Targeted degrader technologies as prospective SARS-CoV-2 therapies","volume":"29","author":"Khurshid","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.drudis.2020.08.007","article-title":"Could PROTACs Protect Us From COVID-19?","volume":"25","author":"Zhou","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1038\/s41467-024-49161-9","article-title":"Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","article-title":"PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication","volume":"31","author":"Tice","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_45","first-page":"340","article-title":"PROTAC induces HIV-1 Nef degradation","volume":"23","author":"Crunkhorn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hilbig, K., Towers, R., Schmitz, M., Bornh\u00e4user, M., Lennig, P., and Zhang, Y. (2024). Cyclosporin A-Based PROTACs Can Deplete Abundant Cellular Cyclophilin A without Suppressing T Cell Activation. Molecules, 29.","DOI":"10.3390\/molecules29122779"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41467-025-56317-8","article-title":"Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV","volume":"16","author":"Newton","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Luo, D., Luo, R., Wang, W., Deng, R., Wang, S., Ma, X., Pu, C., Liu, Y., Zhang, H., and Yu, S. (2024). Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1. Bioorg. Med. Chem. Lett., 111.","DOI":"10.1016\/j.bmcl.2024.129880"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/mmi.14849","article-title":"Targeted protein degradation at the host-pathogen interface","volume":"117","author":"Grohmann","year":"2022","journal-title":"Mol. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ahmad, H., Zia, B., Husain, H., and Husain, A. (2023). Recent Advances in PROTAC-Based Antiviral Strategies. Vaccines, 11.","DOI":"10.3390\/vaccines11020270"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: Advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17568919.2025.2453418","article-title":"PROTACs in the treatment of viral diseases","volume":"17","author":"Bhole","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"110446","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: A graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell Signal"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/16\/3402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:45Z","timestamp":1760034585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/16\/3402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":54,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["molecules30163402"],"URL":"https:\/\/doi.org\/10.3390\/molecules30163402","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}